Search PubMed⌕ Search

Biomedical subjects

L Romani

Publications and source records attributed to L Romani.

142 records · Page 8Linked to original sources
PubMedDate not supplied

Changes in the tumorigenic and metastatic properties of murine melanoma cells treated with a triazene derivative.

Treatment of B16/BL6 murine melanoma cells in vitro with the 'xenogenizing' agent potassium p-(3-methyl-1-triazeno)benzoate (MM-COOK) had a profound impact on the tumorigenic and metastatic properties of the tumor, an effect that was only detectable in immunologically intact hosts. The treated tumor cells gave rise to a considerably smaller number of experimental and spontaneous pulmonary metastases and displayed an impaired growth rate in vivo, but were highly tumorigenic and metastatic in irradiated recipients. Moreover, the drug-treated cells retained the in vitro growth pattern and plating efficiency of the parent line, and were able actively to immunize intact hosts. Studies aimed at clarifying the mechanisms responsible for the decreased metastatic potential of the cells treated with MM-COOK indicated the involvement of host immune responses largely mediated by cells in the T-dependent compartment with no major contribution of natural immunity effector mechanisms.

5-Methylcytosine↗
PubMedDate not supplied

[Clinico-morphological changes in ectropion after treatment with polydeoxyribonucleotide (PDRN)].

Thirty patients in fertile age affected by ectropion were treated with Polydeoxyribonucleotide (PDRN) (*) vaginal suppositories for 24 days. No other local or general therapy was allowed. The following parameters were evaluated: local symptomatology, tolerability and compliance, vaginal cytology, colposcopic examination, bioptic sampling of affected area prior to and after treatment, and local immune response. The results show the efficacy of PDRN. In fact, after the treatment: reduction of subjective symptomatology with decrease of average score for each symptom; excellent or good tolerability and acceptability; reduced inflammation; increased iodine-dark areas; reestablishment of normal balance in T- and B-lymphocytic populations have been found.

Adolescent↗
PubMedDate not supplied

[Myasthenia gravis and pregnancy. Review of the literature and considerations on the immunoprotective effect of alpha-fetoprotein through the observation of a clinical case].

Myasthenia gravis is an autoimmune disorder characterized by a reduction of muscular strength. It is associated with production of anti-acetylcholine-receptor antibodies and with the consequent decrease of muscular acetylcholine receptors. The Authors have studied this pathology during the pregnancy and the puerperium in a myasthenic patient and in her newborn, evaluating seric AChRAbs title and seric alpha-fetoprotein levels, to investigate the possible correlation among these parameters and MG. The study shows that with low seric levels of AChRAbs the mother had a progressive symptomatological impairment of MG from 36th week of pregnancy to term and in puerperium too; the newborn didn't show any sign of pathology. The possible immuno-protective role of alpha-FP in maternal and fetal MG evolution is discussed.

Adult↗
PubMedDate not supplied

[Topical therapy with placental polydeoxyribonucleotide in cervical ectopy and ectropion].

Twenty outpatients, aged 18-45 yrs, with cervical ectropion have been treated with vaginal suppositories of PDRN (a placental derivate). The drug has been given randomly in two preparations of 5 g and 10 g, however both containing the same amount of the active component (5 mg). The results show the effectiveness of the eutrophic and antiphlogistic action of both preparations, with a remarkable reduction of the leukorrhea. The patients preferred the vaginal suppositories of 5g both for the greater maniability and for the smaller vaginal discharge after the administration. The reduction of the excipients in the new vaginal tablets, besides improving the compliance of patients, brings about a longer contact of the drug with the vaginal walls, hence a better bioavailability of the active principle.

Administration, Intravaginal↗